TLX

Telix to Present at Jefferies Healthcare Conference

Retrieved on: 
Tuesday, June 6, 2023
Webcast, AEST, ASX, Conference, TLX, Telix

MELBOURNE, Australia, June 5, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies Healthcare Conference being held in New York from June 7 to June 9, 2023.

Key Points: 
  • MELBOURNE, Australia, June 5, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies Healthcare Conference being held in New York from June 7 to June 9, 2023.
  • The presentation will take place on Wednesday June 7 from 12.30pm – 12.55pm EDT (2.30am – 2.55am AEST, June 8).
  • A live webcast of the presentation will be available at the following link: https://wsw.com/webcast/jeff281/tlx/1727440
    The webcast will be accessible on demand on the Telix website following the event.

Telix to Host Briefing with U.S. Leadership Team and Key Opinion Leaders to Highlight Innovation in Urology

Retrieved on: 
Thursday, May 25, 2023
Radiation, Therapy, The Yale Club of New York City, IX, ASX, TLX, Nuclear medicine, Urology, Pharmaceutical industry, Telix

MELBOURNE, Australia and INDIANAPOLIS, May 25, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it will host an education session for investors on Wednesday, June 21, 2023, at The Yale Club in New York City, from 8.30am – 12.30pm EDT. 

Key Points: 
  • Institutional investors, analysts and company guests are cordially invited to attend the session, which will feature an overview of the Company's growth strategy and product pipeline for the detection and treatment of urological cancers.
  • Speakers will include members of the Telix leadership team, including Managing Director and Group CEO Dr Christian Behrenbruch and U.S.-based executives, Chief Medical Officer Dr Colin Hayward and Telix Americas CEO, Kevin Richardson.
  • The event will also feature key opinion leaders in urology and nuclear medicine to discuss the clinical utility and opportunity for Telix's investigational products.
  • Note: This event is for qualified institutional investors and analysts.

ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller

Retrieved on: 
Monday, May 1, 2023
Surgeon, UCLA Institute for Research on Labor and Employment, AUA, American Urological Association, ASX, Associate, TLX, Renal cell carcinoma, MD, Urology, Patient, CST, PET/CT, Phase, Pharmaceutical industry, Medical imaging, Telix

New data presented demonstrates the high value of TLX250-CDx PET/CT imaging in detecting ccRCC, with secondary analysis confirming utility and effectiveness in very small renal masses, which are prevalent and present a significant diagnostic challenge.

Key Points: 
  • New data presented demonstrates the high value of TLX250-CDx PET/CT imaging in detecting ccRCC, with secondary analysis confirming utility and effectiveness in very small renal masses, which are prevalent and present a significant diagnostic challenge.
  • In very small renal lesions (≤2cm, a secondary endpoint), sensitivity was 84% for all three readers, with specificity 92.3% to 100%.
  • Associate Professor Brian Shuch, MD commented, "It is a great pleasure to be showcasing new data from Telix's Phase III ZIRCON study at AUA, the largest gathering of urologists in the world.
  • We now have analyses on the outcome for very small renal masses, where the data set still shows outstanding sensitivity and specificity, far exceeding confirmatory trial success targets.

ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller

Retrieved on: 
Monday, May 1, 2023
Surgeon, UCLA Institute for Research on Labor and Employment, AUA, American Urological Association, ASX, Associate, TLX, Renal cell carcinoma, MD, Urology, Patient, CST, PET/CT, Phase, Pharmaceutical industry, Medical imaging, Telix

New data presented demonstrates the high value of TLX250-CDx PET/CT imaging in detecting ccRCC, with secondary analysis confirming utility and effectiveness in very small renal masses, which are prevalent and present a significant diagnostic challenge.

Key Points: 
  • New data presented demonstrates the high value of TLX250-CDx PET/CT imaging in detecting ccRCC, with secondary analysis confirming utility and effectiveness in very small renal masses, which are prevalent and present a significant diagnostic challenge.
  • In very small renal lesions (≤2cm, a secondary endpoint), sensitivity was 84% for all three readers, with specificity 92.3% to 100%.
  • Associate Professor Brian Shuch, MD commented, "It is a great pleasure to be showcasing new data from Telix's Phase III ZIRCON study at AUA, the largest gathering of urologists in the world.
  • We now have analyses on the outcome for very small renal masses, where the data set still shows outstanding sensitivity and specificity, far exceeding confirmatory trial success targets.

Introducing the ALL-IN Pack: IM Mastery Academy's Bundle of Digital Education Products and Services

Retrieved on: 
Thursday, April 27, 2023
Pack, FRX, Travel, Student, TBX, Adobe GoLive, SFX, Blaze, TLX, App Store (iOS/iPadOS), Harmonic, ECX, MMX, Google Play, Impulse, DCX, SMX, Social media, Tutoring

NEW YORK, April 27, 2023 /PRNewswire/ -- IM Mastery Academy , a leading online educational platform specializing in financial markets, is proud to announce the launch of the ALL-IN Pack , an all-encompassing bundle of its complete digital education offerings.

Key Points: 
  • NEW YORK, April 27, 2023 /PRNewswire/ -- IM Mastery Academy , a leading online educational platform specializing in financial markets, is proud to announce the launch of the ALL-IN Pack , an all-encompassing bundle of its complete digital education offerings.
  • Key features of the ALL-IN Pack include:
    Live Educator Access: Connect to unlimited interactive online sessions with IM Academy educators via GoLive .
  • All prerecorded content is accessible on mobile devices via the IM Academy app available on the Apple App Store and Google Play .
  • For more information about the ALL-IN Pack and IM Mastery Academy's extensive range of digital education products and services, please visit im.academy.

HONDA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Honda Motor Co., Ltd. and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, April 1, 2023
Class Action Lawsuit, Professional Services, Legal, Odyssey, P.C, II, American Honda Motor Company, Acura TLX, Marketing, Central District, System, ADS, Telephone, Aircraft pilot, Disclosure, Acura, Jeanne Eagels (film), HMC, Person, TLX, District court, Car, Risk, Court, News, NYSE, Passport, Safety, Motorcycle, Automotive industry

Investors have until April 3, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until April 3, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Honda is a multinational conglomerate manufacturer of automobiles, motorcycles and power equipment.
  • The Company’s U.S.-based operations are conducted through its North American subsidiary, American Honda Motor Company, Inc. (“American Honda”).
  • The lawsuit further alleges that American Honda was fully aware of the defect before marketing the vehicles.

Highly Anticipated 2024 Acura Integra Type S Delivers Ultimate Performance; On Sale in June

Retrieved on: 
Tuesday, April 11, 2023
Diamond, Head, V6, TLX, VTEC, Risk, Red and black, Android Auto, Honda Integra, Heart, Torque, DOHC, Android, NSX, SAE, Brain, Apple, Safety, Michelin, Integra, Lane centering, LSD, Red, History, Carbon, IDS, Assistant, Honda Integra (fourth generation), CarPlay, ADS, Acura, Type S, Type, Sale, ELS, Sport, Hydraulic machinery, Tire manufacturing, Mobile phone, Telescopic sight, Heating, ventilation, and air conditioning, Baggage

The 2024 Integra Type S will go on sale this June.

Key Points: 
  • The 2024 Integra Type S will go on sale this June.
  • Integra Type S is available in six striking colours, including the Type S exclusive Tiger Eye Pearl.
  • The driver-focused cabin of the Integra Type S features four-position seating, premium materials and exclusive Type S high-performance details.
  • The new 2024 Integra Type S will be built exclusively at the Marysville Auto Plant in Marysville, Ohio, on the same production line as the Integra, Acura TLX and TLX Type S*.

Highly Anticipated 2024 Acura Integra Type S Delivers Ultimate Street Performance; On Sale in June

Retrieved on: 
Tuesday, April 11, 2023
Diamond, 2019 Acura Grand Prix of Long Beach, Head, V6, Marysville Auto Plant, TLX, VTEC, Risk, Android Auto, Heart, Advanced Compatibility Engineering, Torque, DOHC, Android, Element, NSX, SAE, Brain, Apple, Safety, Symphony No. 4 (Piston), Michelin, Integra, Lane centering, LSD, Carbon, IDS, Assistant, BTC-T Honda Integra Type R, National Pork Producers Council v. Ross, Honda Integra (fourth generation), CarPlay, ADS, Acura, Type S, Type, Sale, ELS, Sport, Hydraulic machinery, Mobile phone, Telescopic sight, Heating, ventilation, and air conditioning, Baggage

"The new Acura Integra Type S puts turbocharged Type S performance and design at the gateway to our brand," said Emile Korkor, Assistant Vice President, Acura National Sales.

Key Points: 
  • "The new Acura Integra Type S puts turbocharged Type S performance and design at the gateway to our brand," said Emile Korkor, Assistant Vice President, Acura National Sales.
  • Integra Type S is available in seven striking colors, including the Type S exclusive Tiger Eye Pearl.
  • The driver-focused cabin of the Integra Type S features four-position seating, premium materials and exclusive Type S high-performance details.
  • The new 2024 Integra Type S will be built exclusively at the Marysville Auto Plant in Marysville, Ohio, on the same production line as the Integra, Acura TLX and TLX Type S*.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Honda Motor Co., Ltd. of Class Action Lawsuit and Upcoming Deadline – HMC

Retrieved on: 
Thursday, March 30, 2023
Odyssey, LLP, II, American Honda Motor Company, Marketing, Central District, System, ADS, Aircraft pilot, Disclosure, Acura, HMC, Person, TLX, Ext, SEC Rule 10b-5, District court, Car, Risk, Honda, Action Replay, Complaint, Court, Pomerantz, News, NYSE, Passport, Safety, Motorcycle, Automotive industry

NEW YORK, March 29, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Honda Motor Co., Ltd. (NYSE: HMC), and certain officers.

Key Points: 
  • NEW YORK, March 29, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Honda Motor Co., Ltd. (NYSE: HMC), and certain officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • The Company’s U.S.-based operations are conducted through its North American subsidiary, American Honda Motor Company, Inc. (“American Honda”).
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RYVYL, Invivyd, Honda, and Allianz and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, March 28, 2023
Odyssey, P.C, Allianz, Acura TLX, Marketing, System, ADS, Class, Acura, HMC, TLX, Register, Car, Risk, News, NYSE, Safety, Motorcycle, Registration statement, Audit, Tobacco, Omicron

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • For more information on the Invivyd class action go to: https://bespc.com/cases/IVVD
    Honda is a multinational conglomerate manufacturer of automobiles, motorcycles and power equipment.
  • Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies.
  • For more information on the Allianz class action go to: https://bespc.com/cases/ALIZY